Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy

Epilepsia

Volumn 51, Issue 5, 2010, Pages 768-772

  Romigi, Andrea ^a,b   Bari, Monica ^a   Placidi, Fabio ^a,b   Grazia Marciani, M ^a,b   Malaponti, Marilena ^b   Torelli, Federico ^a   Izzi, Francesca ^a,b   Prosperetti, Chiara ^a   Zannino, Silvana ^a   Corte, Francesca ^a   Chiaramonte, Carlo ^c   Maccarrone, Mauro ^b,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TERAMO   (Italy)

Author keywords

2 arachidonoylglycerol; Anandamide; Endocannabinoids; Temporal lobe epilepsy

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EPILEPTIC DISCHARGE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TEMPORAL LOBE EPILEPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ARACHIDONIC ACIDS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; EPILEPSY; EPILEPSY, TEMPORAL LOBE; FEMALE; GLYCERIDES; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 77951589098     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02334.x     Document Type: Article

References (28)

1. Ameri A, Wilhelm A, Simmet T. (1999) Effects of the endogenous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br J Pharmacol 126:1831-1839. (Pubitemid 29213102)
2. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M. (2007) The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130:2543-2553.
3. Chevaleyre V, Takahashi KA, Castillo PE. (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37-76.
4. Consroe PF, Wood GC, Buchsbaum H. (1975) Anticonvulsant nature of marihuana smoking. JAMA 234:306-307.
5. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175-185.
6. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. (2007) Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol 558:52-59. (Pubitemid 46328867)
7. Di Marzo V. (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438-455.
8. Engel J Jr. (2001); International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia Jun 42:796-803.
9. French JA. (2007) Refractory epilepsy: clinical overview. Epilepsia 48: 3-7.
10. Freund TF, Katona I, Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066. (Pubitemid 36828930)
11. Gross DW, Hamm J, Ashworth NL, Quigley D. (2004) Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 62:2095-2097. (Pubitemid 38738229)
12. Katona I, Sperlágh B, Sák A, Käfalvi A, Vizi ES, Mackie K, Freund TF. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558. (Pubitemid 29241104)
13. Katona I, Urbán GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF. (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26:5628-5637. (Pubitemid 44315254)
14. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M. (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26:2991-3001.
15. Kozan R, Ayyildiz M, Agar E. (2009) The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats. Epilepsia 50:1760-1767.
16. Ludányi A, Eross L, Czirják S, Vajda J, Halász P, Watanabe M, Palkovits M, Maglóczky Z, Freund TF, Katona I. (2008) Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 28:2976-2990. (Pubitemid 351442292)
17. Maccarrone M, Battista N, Centonze D. (2007) The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 81:349-379. (Pubitemid 46528640)
18. Marsicano G, Lutz B. (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225. (Pubitemid 30009252)
19. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutírrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88. (Pubitemid 37210691)
20. Mechoulam R, Lichtman AH. (2003) Neuroscience. Stout guards of the central nervous system. Science 3; 302:65-67.
21. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B. (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455-466. (Pubitemid 44209321)
22. Mortati K, Dworetzky B, Devinsky O. (2007) Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature Rev Neurol Dis 4:103-106.
23. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 4; 413:527-531. (Pubitemid 32938751)
24. Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD. (1972) Experimental models of epilepsy. Raven Press, New York.
25. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K. (2001a) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 15:21. (Pubitemid 33054840)
26. van der Stelt M, Veldhuis WB, Bär PR, Veldink GA, Vliegenthart JF, Nicolay K. (2001b) Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21:6475-6479.
27. Wallace MJ, Wiley JL, Martin BR, DeLorenzo LJ. (2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428:51-57.
28. Wallace MJ, Martin BR, DeLorenzo RJ. (2002) Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295-301.